What is Low-dose naltrexone (LDN)?

The short answer

Low-dose naltrexone is the drug naltrexone, which is lab-made, in a much smaller amount than usual.

5 sources
Status as of October 4, 2026
How we source
Ellum doesn't sell peptides.

By Ellum EditorialUpdated October 11, 2026AI use

Get updates on Low-dose naltrexone (LDN)

State

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: Low-dose naltrexone (LDN) (1 selected) · edit

Peptides you're interested inLow-dose naltrexone (LDN)

Add another molecule

What we may email you about

Notify me when an Ellum Clinic doctor can see me in my state

Send me updates on Low-dose naltrexone (LDN)

More options (optional): research, doctor contact, paid offers

Contact me about taking part in research (optional)

Send my email, state and peptides to Ellum Clinic or a doctor licensed in my state, so they can contact me about care (optional)

Email me paid offers from clinics and health companies, picked for my peptides and state. Ellum sends them; the companies don't get my details (optional)

What it is

Type: Opioid antagonist (not a peptide)

Regulatory status

Not FDA-approved for this use How we label status

As of October 4, 2026, Low-dose naltrexone (LDN) is not FDA-approved. FDA has approved a drug for human use with the same active ingredient, for alcohol dependence; blocking the effects of opioids (50 mg tablets); preventing relapse to opioid dependence after detox (Vivitrol).

See Low-dose naltrexone (LDN) in the Index →

Federal (FDA): Approved Rx for naltrexone alone only as tablets (ReVia NDA018932 1984, disc.; generic 50 mg ANDAs; SpecGx ANDA076264 also lists 25 and 100 mg) and Vivitrol NDA021897 2006; no naltrexone-alone product below 25 mg is approved. Contrave NDA200063 2014 pairs naltrexone 8 mg with bupropion 90 mg per tablet for weight management (not a low-dose naltrexone product). Low dose is compounded/off-label. No FDA statement on LDN found
503A compounding: Approved-drug component (not in any 503A category) (as of May 14, 2026)
WADA 2026: Not named

References

Sources as of October 4, 2026